Ser688

Site Information
GAEIVyKsPVVsGDt SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 449081

In vivo Characterization
Methods used to characterize site in vivo:	immunoassay ( 7 , 29 , 86 ) , immunoprecipitation ( 5 ) , mass spectrometry ( 3 , 6 , 15 , 16 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 30 , 31 , 32 , 33 , 34 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 65 , 66 , 67 , 68 , 69 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 82 , 83 , 90 ) , microscopy-colocalization with upstream kinase ( 94 ) , mutation of modification site ( 5 ) , phospho-antibody ( 1 , 2 , 5 , 7 , 8 , 9 , 11 , 12 , 13 , 14 , 17 , 29 , 35 , 64 , 70 , 71 , 72 , 81 , 84 , 85 , 86 , 87 , 88 , 89 , 91 , 92 , 93 , 94 ) , western blotting ( 2 , 5 , 7 , 8 , 9 , 11 , 12 , 13 , 29 , 35 , 64 , 71 , 72 , 81 , 84 , 85 , 86 , 88 , 89 , 93 , 94 )
Disease tissue studied:	Alzheimer's disease ( 1 , 7 , 11 , 14 , 94 ) , anthrax infection ( 27 ) , brain cancer ( 20 , 21 , 22 , 23 , 24 ) , neuroblastoma ( 2 , 5 , 9 , 85 , 89 ) , neuroendocrine cancer ( 20 , 21 , 22 , 23 , 24 ) , melanoma skin cancer ( 45 ) , Lafora disease ( 35 )
Relevant cell line - cell type - tissue:	'brain, cerebellum' ( 69 , 88 , 93 ) , 'brain, cerebral cortex' ( 9 , 12 , 17 , 69 , 82 , 84 , 86 ) , 'brain, cerebrum' ( 88 , 93 ) , 'brain, embryonic' ( 25 , 26 , 34 , 37 , 38 , 39 , 40 , 43 , 44 , 54 , 58 , 60 , 66 , 68 , 74 , 75 , 76 , 77 , 79 , 94 ) , 'brain, forebrain' ( 63 , 92 ) , 'brain, forebrain' [CDK5R1 (mouse), transgenic] ( 92 ) , 'brain, hippocampus' ( 9 , 17 , 81 , 86 , 94 ) , 'brain, hippocampus' [APP (human), transgenic] ( 11 ) , 'brain, hippocampus, dentate gyrus' ( 69 ) , 'brain, midbrain' ( 69 ) , 'brain, striatum' ( 29 ) , 'fat, brown' ( 30 ) , 'neuron, cerebellar granule'-brain ( 87 ) , 'neuron, hippocampal'-brain ( 70 ) , 'neuron, hippocampal, CA1 pyramidal'-brain ( 7 ) , 293 (epithelial) ( 5 ) , brain ( 1 , 8 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 30 , 31 , 32 , 33 , 36 , 41 , 42 , 49 , 50 , 51 , 52 , 53 , 56 , 57 , 59 , 64 , 65 , 71 , 72 , 78 , 80 , 91 , 94 ) , brain [CDK5R1 (mouse)] ( 71 ) , brain [laforin (mouse), homozygous knockout] ( 35 ) , C2C12 (myoblast) ( 46 , 47 , 48 ) , COS (fibroblast) ( 35 ) , heart ( 16 , 30 , 55 , 61 , 67 ) , kidney ( 30 ) , liver ( 3 , 15 , 30 , 62 , 83 ) , lung ( 30 ) , muscle [laforin (mouse), homozygous knockout] ( 35 ) , Neuro-2a (neuron) ( 2 , 85 , 89 ) , neuron ( 13 ) , neuron-'brain, cerebral cortex' ( 14 ) , neuron-'brain, hippocampus' ( 5 ) , neuron:postsynaptic density-'brain, hippocampus, CA1 region' ( 6 ) , neuron:synaptosome-'brain, forebrain' ( 90 ) , P19 (testicular) ( 73 ) , SH-SY5Y (neural crest) ( 5 ) , skin [mGluR1 (mouse), transgenic, TG mutant mice] ( 45 ) , SKNSH (neural crest) ( 9 ) , spleen ( 27 , 30 ) , testis ( 30 )

Upstream Regulation
Regulatory protein:	Akt1 (mouse) ( 72 ) , APP (human) ( 84 ) , APP (mouse) ( 9 , 85 ) , CAMKK2 (mouse) ( 28 ) , CDK5R1 (mouse) ( 71 , 92 ) , DVL1 (mouse) ( 89 ) , GSK3B (mouse) ( 72 ) , laforin (mouse) ( 35 ) , NPC1 (mouse) ( 88 , 93 ) , PAR1 (mouse) ( 72 ) , PSEN1 (mouse) ( 9 ) , SERPINA3 (human) ( 84 ) , SNCA (mouse) ( 29 ) , TREM2 (mouse) ( 1 ) , VPS4A (human) ( 2 )
Putative in vivo kinases:	CDK5 (mouse) ( 9 ) , GSK3B (mouse) ( 9 , 29 )
Putative upstream phosphatases:	laforin (mouse) ( 35 )
Phosphatases, in vitro:	laforin (mouse) ( 35 )
Treatments:	anti-tau_antibody_ ( 14 ) , antichymotrypsin ( 84 ) , beta-amyloid_42 ( 5 , 28 ) , cold_water_stress ( 81 ) , DI-PHPB ( 9 ) , donepezil ( 11 ) , ether ( 81 ) , fasting ( 86 ) , glucose_starvation ( 91 ) , hibernating ( 64 ) , lithium ( 70 , 85 ) , long-term_potentiation ( 6 ) , MDMA ( 70 ) , olfactory bulbectomy ( 7 ) , partial_hepatectomy ( 1 ) , refeeding ( 86 ) , retinoic_acid ( 73 ) , seliciclib ( 70 , 85 ) , summer-active ( 64 ) , wortmannin ( 89 ) , xanthoceraside ( 11 )

Downstream Regulation
Effects of modification on Tau:	intracellular localization ( 12 ) , molecular association, regulation ( 29 ) , phosphorylation ( 5 ) , protein conformation ( 29 )
Induce interaction with:	SNCA (mouse) ( 29 )

Disease / Diagnostics Relevance
Relevant diseases:	Alzheimer's disease ( 7 , 9 ) , Parkinson's disease ( 8 , 29 )

References
1	Jiang Y, et al. (2018) Upregulation of TREM2 Ameliorates Neuroinflammatory Responses and Improves Cognitive Deficits Triggered by Surgical Trauma in Appswe/PS1dE9 Mice. Cell Physiol Biochem 46, 1398-1411 29689568 Curated Info
2	Willén K, et al. (2017) Aβ accumulation causes MVB enlargement and is modelled by dominant negative VPS4A. Mol Neurodegener 12, 61 28835279 Curated Info
3	Robles MS, Humphrey SJ, Mann M (2017) Phosphorylation Is a Central Mechanism for Circadian Control of Metabolism and Physiology. Cell Metab 25, 118-127 27818261 Curated Info
4	Sacco F, et al. (2016) Glucose-regulated and drug-perturbed phosphoproteome reveals molecular mechanisms controlling insulin secretion. Nat Commun 7, 13250 27841257 Curated Info
5	Kam TI, et al. (2016) FcγRIIb-SHIP2 axis links Aβ to tau pathology by disrupting phosphoinositide metabolism in Alzheimer's disease model. Elife 5 27834631 Curated Info
6	Li J, et al. (2016) Long-term potentiation modulates synaptic phosphorylation networks and reshapes the structure of the postsynaptic interactome. Sci Signal 9, rs8 27507650 Curated Info
7	Li K, et al. (2016) Olfactory Deprivation Hastens Alzheimer-Like Pathologies in a Human Tau-Overexpressed Mouse Model via Activation of cdk5. Mol Neurobiol 53, 391-401 25465240 Curated Info
8	Credle JJ, et al. (2015) GSK-3β dysregulation contributes to parkinson's-like pathophysiology with associated region-specific phosphorylation and accumulation of tau and α-synuclein. Cell Death Differ 22, 838-51 25394490 Curated Info
9	Peng Y, et al. (2014) Potassium 2-(1-Hydroxypentyl)-Benzoate Improves Memory Deficits and Attenuates Amyloid and τ Pathologies in a Mouse Model of Alzheimer's Disease. J Pharmacol Exp Ther 350, 361-74 24893984 Curated Info
10	Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704 24719451 Curated Info
11	Jin G, et al. (2014) Xanthoceraside rescues learning and memory deficits through attenuating beta-amyloid deposition and tau hyperphosphorylation in APP mice. Neurosci Lett 573, 58-63 24810883 Curated Info
12	Sahara N, et al. (2014) Biochemical Distribution of Tau Protein in Synaptosomal Fraction of Transgenic Mice Expressing Human P301L Tau. Front Neurol 5, 26 24653715 Curated Info
13	Congdon EE, Gu J, Sait HB, Sigurdsson EM (2013) Antibody Uptake into Neurons Occurs Primarily via Clathrin-dependent Fcγ Receptor Endocytosis and Is a Prerequisite for Acute Tau Protein Clearance. J Biol Chem 288, 35452-65 24163366 Curated Info
14	Yanamandra K, et al. (2013) Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron 80, 402-14 24075978 Curated Info
15	Wilson-Grady JT, Haas W, Gygi SP (2013) Quantitative comparison of the fasted and re-fed mouse liver phosphoproteomes using lower pH reductive dimethylation. Methods 61, 277-86 23567750 Curated Info
16	Lundby A, et al. (2013) In vivo phosphoproteomics analysis reveals the cardiac targets of β-adrenergic receptor signaling. Sci Signal 6, rs11 23737553 Curated Info
17	Brownlow ML, et al. (2013) Ketogenic diet improves motor performance but not cognition in two mouse models of Alzheimer's pathology. PLoS One 8, e75713 24069439 Curated Info
18	Trinidad JC, et al. (2012) Global identification and characterization of both O-GlcNAcylation and phosphorylation at the murine synapse. Mol Cell Proteomics 11, 215-29 22645316 Curated Info
19	Goswami T, et al. (2012) Comparative phosphoproteomic analysis of neonatal and adult murine brain. Proteomics 12, 2185-9 22807455 Curated Info
20	Guo A (2011) CST Curation Set: 12732; Year: 2011; Biosample/Treatment: tissue, brain/untreated; Disease: brain cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) CDKs Substrate Antibody Cat#: 2324, PTMScan(R) Phospho-CDK Substrate Motif (K/RS*PXK/R) Immunoaffinity Beads Cat#: 1981 Curated Info
21	Guo A (2011) CST Curation Set: 12733; Year: 2011; Biosample/Treatment: tissue, brain/untreated; Disease: brain cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) CDKs Substrate Antibody Cat#: 2324, PTMScan(R) Phospho-CDK Substrate Motif (K/RS*PXK/R) Immunoaffinity Beads Cat#: 1981 Curated Info
22	Guo A (2011) CST Curation Set: 12734; Year: 2011; Biosample/Treatment: tissue, brain/untreated; Disease: brain cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) CDKs Substrate Antibody Cat#: 2324, PTMScan(R) Phospho-CDK Substrate Motif (K/RS*PXK/R) Immunoaffinity Beads Cat#: 1981 Curated Info
23	Guo A (2011) CST Curation Set: 12735; Year: 2011; Biosample/Treatment: tissue, brain/untreated; Disease: brain cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) CDKs Substrate Antibody Cat#: 2324, PTMScan(R) Phospho-CDK Substrate Motif (K/RS*PXK/R) Immunoaffinity Beads Cat#: 1981 Curated Info
24	Guo A (2011) CST Curation Set: 12737; Year: 2011; Biosample/Treatment: tissue, brain/untreated; Disease: brain cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
25	Guo A (2011) CST Curation Set: 12476; Year: 2011; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Curated Info
26	Guo A (2011) CST Curation Set: 12482; Year: 2011; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Curated Info
27	Manes NP, et al. (2011) Discovery of mouse spleen signaling responses to anthrax using label-free quantitative phosphoproteomics via mass spectrometry. Mol Cell Proteomics 10, M110.000927 21189417 Curated Info
28	Thornton C, et al. (2011) AMP-activated protein kinase (AMPK) is a tau kinase, activated in response to amyloid β-peptide exposure. Biochem J 434, 503-12 21204788 Curated Info
29	Wills J, et al. (2011) Tauopathic changes in the striatum of A53T α-synuclein mutant mouse model of Parkinson's disease. PLoS One 6, e17953 21445308 Curated Info
30	Huttlin EL, et al. (2010) A tissue-specific atlas of mouse protein phosphorylation and expression. Cell 143, 1174-89 21183079 Curated Info
31	Possemato A (2010) CST Curation Set: 9879; Year: 2010; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]XP Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) 14-3-3 Binding Motif (4E2) Mouse mAb Cat#: 9606 Curated Info
32	Possemato A (2010) CST Curation Set: 9878; Year: 2010; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]XP Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) 14-3-3 Binding Motif (4E2) Mouse mAb Cat#: 9606 Curated Info
33	Wiśniewski JR, et al. (2010) Brain phosphoproteome obtained by a FASP-based method reveals plasma membrane protein topology. J Proteome Res 9, 3280-9 20415495 Curated Info
34	Zhou J (2010) CST Curation Set: 9272; Year: 2010; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y)XpS Curated Info
35	Puri R, Suzuki T, Yamakawa K, Ganesh S (2009) Hyperphosphorylation and aggregation of Tau in laforin-deficient mice, an animal model for Lafora disease. J Biol Chem 284, 22657-63 19542233 Curated Info
36	Zhou J (2009) CST Curation Set: 7431; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pSP Curated Info
37	Zhou J (2009) CST Curation Set: 7428; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pSP Curated Info
38	Zhou J (2009) CST Curation Set: 7429; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pSP Curated Info
39	Zhou J (2009) CST Curation Set: 7381; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: QXp[ST] Curated Info
40	Zhou J (2009) CST Curation Set: 7382; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: QXp[ST] Curated Info
41	Zhou J (2009) CST Curation Set: 7375; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: YXp[ST] Curated Info
42	Zhou J (2009) CST Curation Set: 7376; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: YXp[ST] Curated Info
43	Zhou J (2009) CST Curation Set: 7373; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: YXp[ST] Curated Info
44	Zhou J (2009) CST Curation Set: 7374; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: YXp[ST] Curated Info
45	Zanivan S, et al. (2008) Solid tumor proteome and phosphoproteome analysis by high resolution mass spectrometry. J Proteome Res 7, 5314-26 19367708 Curated Info
46	Possemato A (2008) CST Curation Set: 5027; Year: 2008; Biosample/Treatment: cell line, C2C12/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
47	Possemato A (2008) CST Curation Set: 5028; Year: 2008; Biosample/Treatment: cell line, C2C12/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
48	Possemato A (2008) CST Curation Set: 5033; Year: 2008; Biosample/Treatment: cell line, C2C12/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
49	Guo A (2008) CST Curation Set: 5004; Year: 2008; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) CDKs Substrate Antibody Cat#: 2324, PTMScan(R) Phospho-CDK Substrate Motif (K/RS*PXK/R) Immunoaffinity Beads Cat#: 1981 Curated Info
50	Guo A (2008) CST Curation Set: 5005; Year: 2008; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) CDKs Substrate Antibody Cat#: 2324, PTMScan(R) Phospho-CDK Substrate Motif (K/RS*PXK/R) Immunoaffinity Beads Cat#: 1981 Curated Info
51	Guo A (2008) CST Curation Set: 5006; Year: 2008; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) CDKs Substrate Antibody Cat#: 2324, PTMScan(R) Phospho-CDK Substrate Motif (K/RS*PXK/R) Immunoaffinity Beads Cat#: 1981 Curated Info
52	Guo A (2008) CST Curation Set: 5007; Year: 2008; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) CDKs Substrate Antibody Cat#: 2324, PTMScan(R) Phospho-CDK Substrate Motif (K/RS*PXK/R) Immunoaffinity Beads Cat#: 1981 Curated Info
53	Zhou J (2008) CST Curation Set: 4863; Year: 2008; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-Thr-Pro Motif Antibody (polyAB) Cat#: 3003, PTMScan(R) Phospho-Thr-Pro Motif (T*P) Immunoaffinity Beads Cat#: 1996 Curated Info
54	Zhou J (2008) CST Curation Set: 4864; Year: 2008; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-Thr-Pro Motif Antibody (polyAB) Cat#: 3003, PTMScan(R) Phospho-Thr-Pro Motif (T*P) Immunoaffinity Beads Cat#: 1996 Curated Info
55	Zhou J (2008) CST Curation Set: 4865; Year: 2008; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-Thr-Pro Motif Antibody (polyAB) Cat#: 3003, PTMScan(R) Phospho-Thr-Pro Motif (T*P) Immunoaffinity Beads Cat#: 1996 Curated Info
56	Zhou J (2008) CST Curation Set: 4859; Year: 2008; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Curated Info
57	Zhou J (2008) CST Curation Set: 4779; Year: 2008; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pTXR Antibodies Used to Purify Peptides prior to LCMS: Phospho-Threonine-X-Arginine Antibody Cat#: 2351, PTMScan(R) Phospho-Thr-X-Arg Motif (T*XR) Immunoaffinity Beads Cat#: 1988 Curated Info
58	Zhou J (2008) CST Curation Set: 4781; Year: 2008; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pTXR Antibodies Used to Purify Peptides prior to LCMS: Phospho-Threonine-X-Arginine Antibody Cat#: 2351, PTMScan(R) Phospho-Thr-X-Arg Motif (T*XR) Immunoaffinity Beads Cat#: 1988 Curated Info
59	Zhou J (2008) CST Curation Set: 4784; Year: 2008; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) CDKs Substrate Antibody Cat#: 2324, PTMScan(R) Phospho-CDK Substrate Motif (K/RS*PXK/R) Immunoaffinity Beads Cat#: 1981 Curated Info
60	Zhou J (2008) CST Curation Set: 4785; Year: 2008; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) CDKs Substrate Antibody Cat#: 2324, PTMScan(R) Phospho-CDK Substrate Motif (K/RS*PXK/R) Immunoaffinity Beads Cat#: 1981 Curated Info
61	Zhou J (2008) CST Curation Set: 4786; Year: 2008; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) CDKs Substrate Antibody Cat#: 2324, PTMScan(R) Phospho-CDK Substrate Motif (K/RS*PXK/R) Immunoaffinity Beads Cat#: 1981 Curated Info
62	Zhou J (2008) CST Curation Set: 4787; Year: 2008; Biosample/Treatment: tissue, liver/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) CDKs Substrate Antibody Cat#: 2324, PTMScan(R) Phospho-CDK Substrate Motif (K/RS*PXK/R) Immunoaffinity Beads Cat#: 1981 Curated Info
63	Collins MO, et al. (2008) Phosphoproteomic analysis of the mouse brain cytosol reveals a predominance of protein phosphorylation in regions of intrinsic sequence disorder. Mol Cell Proteomics 7, 1331-48 18388127 Curated Info
64	Su B, et al. (2008) Physiological regulation of tau phosphorylation during hibernation. J Neurochem 105, 2098-108 18284615 Curated Info
65	Zhou J (2008) CST Curation Set: 4338; Year: 2008; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pSP Curated Info
66	Zhou J (2008) CST Curation Set: 4339; Year: 2008; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pSP Curated Info
67	Zhou J (2008) CST Curation Set: 4340; Year: 2008; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pSP Curated Info
68	Zhou J (2008) CST Curation Set: 4323; Year: 2008; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Curated Info
69	Trinidad JC, et al. (2008) Quantitative analysis of synaptic phosphorylation and protein expression. Mol Cell Proteomics 7, 684-96 18056256 Curated Info
70	Busceti CL, et al. (2008) Enhanced tau phosphorylation in the hippocampus of mice treated with 3,4-methylenedioxymethamphetamine ("Ecstasy"). J Neurosci 28, 3234-45 18354027 Curated Info
71	Wen Y, et al. (2008) Interplay between cyclin-dependent kinase 5 and glycogen synthase kinase 3 beta mediated by neuregulin signaling leads to differential effects on tau phosphorylation and amyloid precursor protein processing. J Neurosci 28, 2624-32 18322105 Curated Info
72	Dickey CA, et al. (2008) Akt and CHIP coregulate tau degradation through coordinated interactions. Proc Natl Acad Sci U S A 105, 3622-7 18292230 Curated Info
73	Smith JC, et al. (2007) A differential phosphoproteomic analysis of retinoic acid-treated P19 cells. J Proteome Res 6, 3174-86 17622165 Curated Info
74	Guo A (2007) CST Curation Set: 2901; Year: 2007; Biosample/Treatment: tissue, brain/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986 Curated Info
75	Guo A (2007) CST Curation Set: 2715; Year: 2007; Biosample/Treatment: tissue, brain/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
76	Guo A (2007) CST Curation Set: 2717; Year: 2007; Biosample/Treatment: tissue, brain/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST](D/E)X(D/E) Curated Info
77	Guo A (2007) CST Curation Set: 2672; Year: 2007; Biosample/Treatment: tissue, brain/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
78	Guo A (2007) CST Curation Set: 2675; Year: 2007; Biosample/Treatment: tissue, brain/LY; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
79	Guo A (2007) CST Curation Set: 2677; Year: 2007; Biosample/Treatment: tissue, brain/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) ATM/ATR Substrate Antibody Cat#: 2851 Curated Info
80	Guo A (2007) CST Curation Set: 2682; Year: 2007; Biosample/Treatment: tissue, brain/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) ATM/ATR Substrate Antibody Cat#: 2851 Curated Info
81	Ikeda Y, Ishiguro K, Fujita SC (2007) Ether stress-induced Alzheimer-like tau phosphorylation in the normal mouse brain. FEBS Lett 581, 891-7 17289030 Curated Info
82	Munton RP, et al. (2007) Qualitative and quantitative analyses of protein phosphorylation in naive and stimulated mouse synaptosomal preparations. Mol Cell Proteomics 6, 283-93 17114649 Curated Info
83	Villén J, Beausoleil SA, Gerber SA, Gygi SP (2007) Large-scale phosphorylation analysis of mouse liver. Proc Natl Acad Sci U S A 104, 1488-93 17242355 Curated Info
84	Padmanabhan J, Levy M, Dickson DW, Potter H (2006) Alpha1-antichymotrypsin, an inflammatory protein overexpressed in Alzheimer's disease brain, induces tau phosphorylation in neurons. Brain 129, 3020-34 16987932 Curated Info
85	Wang ZF, et al. (2006) Effects of endogenous beta-amyloid overproduction on tau phosphorylation in cell culture. J Neurochem 98, 1167-75 16762022 Curated Info
86	Li X, Lu F, Wang JZ, Gong CX (2006) Concurrent alterations of O-GlcNAcylation and phosphorylation of tau in mouse brains during fasting. Eur J Neurosci 23, 2078-86 16630055 Curated Info
87	Cheng CM, et al. (2005) Tau is hyperphosphorylated in the insulin-like growth factor-I null brain. Endocrinology 146, 5086-91 16123158 Curated Info
88	Yu W, Ko M, Yanagisawa K, Michikawa M (2005) Neurodegeneration in heterozygous Niemann-Pick type C1 (NPC1) mouse: implication of heterozygous NPC1 mutations being a risk for tauopathy. J Biol Chem 280, 27296-302 15919659 Curated Info
89	Wang HH, et al. (2005) Overexpression of dishevelled-1 attenuates wortmannin-induced hyperphosphorylation of cytoskeletal proteins in N2a cell. Acta Pharmacol Sin 26, 679-84 15916733 Curated Info
90	Collins MO, et al. (2005) Proteomic analysis of in vivo phosphorylated synaptic proteins. J Biol Chem 280, 5972-82 15572359 Curated Info
91	Liu F, et al. (2004) O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer's disease. Proc Natl Acad Sci U S A 101, 10804-9 15249677 Curated Info
92	Cruz JC, et al. (2003) Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles. Neuron 40, 471-83 14642273 Curated Info
93	Sawamura N, et al. (2001) Site-specific phosphorylation of tau accompanied by activation of mitogen-activated protein kinase (MAPK) in brains of Niemann-Pick type C mice. J Biol Chem 276, 10314-9 11152466 Curated Info
94	Jicha GA, et al. (1999) cAMP-dependent protein kinase phosphorylations on tau in Alzheimer's disease. J Neurosci 19, 7486-94 10460255 Curated Info